Industry news

Share this article:
The FDA, in partnership with Duke University, announced the executive board for its Clinical Trials Transformation Initiative. The board will be co-chaired by Duke vice chancellor for clinical research Dr. Robert Califf and Dr. Rachel Behrman, director of the Office of Critical Path Programs at FDA. Industry representation on the board includes: Susan Alpert, SVP and chief quality and regulatory officer at Medtronic; Glenn Gormley, SVP, global clinical development and medical affairs, Novartis Pharmaceuticals; and Jay Siegel, group president, R&D, biotechnology, immunology and oncology at Johnson & Johnson. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters